Sweeping Change At FTC May Sweep Away RCT Standard For Health Claims
This article was originally published in The Rose Sheet
Confirmations by the Senate mark FTC ’s first-ever complete leadership turnover at once and fill out the roster for the first time since President Trump’s election in 2016. The agency has been operating with two commissioners since soon after the election.
You may also be interested in...
An FTC member doubts NeuroMetrix crossed all FDA regulatory lines in advertising for Quell wearable pain relief technology that attorneys alleged. FDA warning letter says Zona Health executives said they “would ‘remain in all regulatory guidelines’" when the agency in 2018 explained claims violations.
Ohlhausen exits FTC; Morrow heads HempMeds; and Messing recruits for PainTx advisory board.
FTC Bureau of Consumer Protection official Richard Cleland takes on the hot-button issue by explaining that a supplement health or structure/function claim doesn't need support from research with the size and scope of studies looking at the safety and efficacy of a drug ingredient proposed for a certain indication. Supplement ad claims, though, still need competent and reliable scientific evidence as support.